MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+49-89-899270
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$113.72 million
Profitability
Miscellaneous
Employees329
Next Earnings Date10/29/2019 (Estimated)
OptionableNot Optionable
MorphoSys (ETR:MOR) Frequently Asked Questions
What is MorphoSys' stock symbol?
MorphoSys trades on the ETR under the ticker symbol "MOR."
When is MorphoSys' next earnings date?
What price target have analysts set for MOR?
9 brokers have issued twelve-month price objectives for MorphoSys' shares. Their predictions range from €81.00 to €150.00. On average, they anticipate MorphoSys' share price to reach €119.78 in the next year. This suggests a possible upside of 20.6% from the stock's current price. View Analyst Price Targets for MorphoSys.
What is the consensus analysts' recommendation for MorphoSys?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MorphoSys.
Has MorphoSys been receiving favorable news coverage?
Media coverage about MOR stock has been trending somewhat negative on Friday, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. MorphoSys earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for MorphoSys.
Who are some of MorphoSys' key competitors?
Some companies that are related to MorphoSys include Cronos Group (CRON), BTG (BTG), Asterias Biotherapeutics (AST), Abcam (ABC), Genus (GNS), Polynovo (PNV), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), Mesoblast (MSB), Kodiak Sciences (KOD), Paradigm Biopharmaceuticals (PAR), BELLUS Health (BLU), Biotest (BIO), Neptune Wellness Solutions (NEPT) and Starpharma (SPL).
What other stocks do shareholders of MorphoSys own?
Who are MorphoSys' key executives?
MorphoSys' management team includes the folowing people:
- Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 59)
- Mr. Jens H. Holstein, CFO & Member of Management Board (Age 55)
- Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 49)
- Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 57)
- Mr. Klaus De Wall, Head of Accounting & Tax
What is MorphoSys' stock price today?
One share of MOR stock can currently be purchased for approximately €99.35.
How big of a company is MorphoSys?
What is MorphoSys' official website?
How can I contact MorphoSys?
MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.
MarketBeat Community Rating for MorphoSys (ETR MOR)
MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
